Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Glioma × ivosidenib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myeloid, Acute 2 Leukemia 2 Cholangiocarcinoma 2 Neoplasms, Unknown Primary 1 Glioma 1

Interventions

Temozolomide 42 Bevacizumab 38 Radiotherapy 16 Magnetic Resonance Spectroscopy 12 Irinotecan 11 Nivolumab 7 Everolimus 6 Radiation 5 Carboplatin 5 poly ICLC 4 pembrolizumab 4 X-Rays 4 Phantoms, Imaging 4 Erlotinib Hydrochloride 4 Carmustine 4 ribociclib 3 fluorodopa F 18 3 Vorinostat 3 Specimen Handling 3 Radiotherapy, Intensity-Modulated 3 Radiosurgery 3 Nuclear Medicine Department, Hospital 3 Modafinil 3 Lomustine 3 trametinib 2 selinexor 2 plerixafor 2 perampanel 2 palbociclib 2 lenvatinib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04056910 2025-02-27

Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors

University of Pittsburgh

Phase 2 Completed

15 enrolled 14 charts

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡